Elan drug approved by FDA

Elan today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s pain treatment PRIALT(R).

The drug is designed for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment.